DOVA IS…
…a clinical-stage pharmaceutical company focused on acquiring, developing and commercializing drug candidates for rare diseases where there is a high unmet medical need. With a nimble approach and a team of bright minds aglow with passion, we’re dedicated to bringing brilliant medicine to market.
Dova Pharmaceuticals to Present at Evercore ISI Conference Tue, 21 Nov 2017 13:30:00 +0000 DURHAM, N.C., Nov. 21, 2017-- Dova Pharmaceuticals, Inc. today announced that Alex Sapir, President and Chief Executive Officer, will present a company overview at the Evercore ISI Biopharma Catalyst/Deep ...
What You Must Know About Dova Pharmaceuticals Inc’s (DOVA) Financial Strength Wed, 15 Nov 2017 19:47:08 +0000 Investors are always looking for growth in small-cap stocks like Dova Pharmaceuticals Inc (NASDAQ:DOVA), with a market cap of USD $578.98M. However, an important fact which most ignore is: howRead More...
Dova Pharmaceuticals to Present at Jefferies 2017 London Healthcare Conference Fri, 10 Nov 2017 13:30:00 +0000 DURHAM, N.C., Nov. 10, 2017-- Dova Pharmaceuticals, Inc. today announced that Alex Sapir, President and Chief Executive Officer, will present a company overview at the Jefferies 2017 London Healthcare ...
Dova Pharmaceuticals reports 3Q loss Thu, 09 Nov 2017 23:05:53 +0000 The Durham, North Carolina-based company said it had a loss of 38 cents per share. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
Dova Pharmaceuticals Reports Third Quarter 2017 Operating and Financial Results Thu, 09 Nov 2017 21:05:00 +0000 NDA for avatrombopag submitted to FDA. Conference call scheduled for 4:30 p.m. EST today. DURHAM, N.C., Nov. 09, 2017-- Dova Pharmaceuticals, Inc. today reported its operating and financial results for ...
43% Upside Seen For Dova Pharma Following Competitor Product's Poor Results Tue, 26 Sep 2017 13:10:42 +0000 Analysts at Leerink turned bullish on Dova Pharmaceuticals Inc (NASDAQ: DOVA ) after a competitor to the clinical-stage pharmaceutical company reported disappointing results from a phase 3 trial. Japan-based ...
Dova Pharmaceuticals to Present at 2017 Leerink Partners Rare Disease Roundtable Wed, 20 Sep 2017 20:15:00 +0000 DURHAM, N.C., Sept. 20, 2017-- Dova Pharmaceuticals, Inc. today announced that Alex Sapir, President and Chief Executive Officer, will present a company overview at the 2017 Leerink Partners Rare Disease ...
*Winners defined as our Top Picks that increased 20% or more within a 6-month period.
Red Letters imply that that particular criteria did not meet minimum requirements, e.g., a low GSA Rank would show it in red.
___ Red Line On Graph Shows a Trailing Stop Loss Based on Support and Resistance Levels. See how it works.
___ Blue Line On Graph Shows the 10-Week Moving Average.
___ Magenta Line On Graph Shows the 40-Week Moving Average.
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.